Cargando…
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351040/ https://www.ncbi.nlm.nih.gov/pubmed/37465684 http://dx.doi.org/10.3389/fimmu.2023.1227797 |
_version_ | 1785074255626502144 |
---|---|
author | Wang, Luyao Yang, Zongxing Guo, Fucheng Chen, Yurong Wei, Jiarui Dai, Xiangpeng Zhang, Xiaoling |
author_facet | Wang, Luyao Yang, Zongxing Guo, Fucheng Chen, Yurong Wei, Jiarui Dai, Xiangpeng Zhang, Xiaoling |
author_sort | Wang, Luyao |
collection | PubMed |
description | Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD-L1 therapy. Therefore, it is of importance to predict the response to immunotherapy for the precision treatment of patients. Although the expression of PD-L1 and tumor mutation burden (TMB) are commonly used to predict the clinical response of anti-PD-1/PD-L1 therapy, other factors such as tumor-specific genes, dMMR/MSI, and gut microbiome are also promising predictors for immunotherapy in lung cancer. Furthermore, invasive peripheral blood biomarkers including blood DNA-related biomarkers (e.g., ctDNA and bTMB), blood cell-related biomarkers (e.g., immune cells and TCR), and other blood-related biomarkers (e.g., soluble PD-L1 and cytokines) were utilized to predict the immunotherapeutic response. In this review, the current achievements of anti-PD-1/PD-L1 therapy and the potential biomarkers for the prediction of anti-PD-1/PD-L1 immunotherapy in lung cancer treatment were summarized and discussed. |
format | Online Article Text |
id | pubmed-10351040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103510402023-07-18 Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer Wang, Luyao Yang, Zongxing Guo, Fucheng Chen, Yurong Wei, Jiarui Dai, Xiangpeng Zhang, Xiaoling Front Immunol Immunology Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD-L1 therapy. Therefore, it is of importance to predict the response to immunotherapy for the precision treatment of patients. Although the expression of PD-L1 and tumor mutation burden (TMB) are commonly used to predict the clinical response of anti-PD-1/PD-L1 therapy, other factors such as tumor-specific genes, dMMR/MSI, and gut microbiome are also promising predictors for immunotherapy in lung cancer. Furthermore, invasive peripheral blood biomarkers including blood DNA-related biomarkers (e.g., ctDNA and bTMB), blood cell-related biomarkers (e.g., immune cells and TCR), and other blood-related biomarkers (e.g., soluble PD-L1 and cytokines) were utilized to predict the immunotherapeutic response. In this review, the current achievements of anti-PD-1/PD-L1 therapy and the potential biomarkers for the prediction of anti-PD-1/PD-L1 immunotherapy in lung cancer treatment were summarized and discussed. Frontiers Media S.A. 2023-07-03 /pmc/articles/PMC10351040/ /pubmed/37465684 http://dx.doi.org/10.3389/fimmu.2023.1227797 Text en Copyright © 2023 Wang, Yang, Guo, Chen, Wei, Dai and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Luyao Yang, Zongxing Guo, Fucheng Chen, Yurong Wei, Jiarui Dai, Xiangpeng Zhang, Xiaoling Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer |
title | Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer |
title_full | Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer |
title_fullStr | Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer |
title_full_unstemmed | Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer |
title_short | Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer |
title_sort | research progress of biomarkers in the prediction of anti-pd-1/pd-l1 immunotherapeutic efficiency in lung cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351040/ https://www.ncbi.nlm.nih.gov/pubmed/37465684 http://dx.doi.org/10.3389/fimmu.2023.1227797 |
work_keys_str_mv | AT wangluyao researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer AT yangzongxing researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer AT guofucheng researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer AT chenyurong researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer AT weijiarui researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer AT daixiangpeng researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer AT zhangxiaoling researchprogressofbiomarkersinthepredictionofantipd1pdl1immunotherapeuticefficiencyinlungcancer |